Switch theme
Sign up to access all valuation multiples
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
2015
14
Last FY Revenue n/a
LTM EBITDA -$25.3M
$329M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Palvella Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$25.3M.
In the most recent fiscal year, Palvella Therapeutics achieved revenue of n/a and an EBITDA of -$13.1M.
Palvella Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Palvella Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$25.3M | XXX | -$13.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$25.8M | XXX | -$14.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$27.5M | XXX | -$17.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 1, 2025, Palvella Therapeutics's stock price is $37.
Palvella Therapeutics has current market cap of $404M, and EV of $329M.
See Palvella Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $329M | $404M | XXX | XXX | XXX | XXX | $-5.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 1, 2025, Palvella Therapeutics has market cap of $404M and EV of $329M.
Palvella Therapeutics's trades at n/a EV/Revenue multiple, and -25.1x EV/EBITDA.
Equity research analysts estimate Palvella Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Palvella Therapeutics has a P/E ratio of -14.7x.
See valuation multiples for Palvella Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $404M | XXX | $404M | XXX | XXX | XXX |
| EV (current) | $329M | XXX | $329M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -13.0x | XXX | -25.1x | XXX | XXX | XXX |
| EV/EBIT | -12.8x | XXX | -23.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.7x | XXX | -23.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -30.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPalvella Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
Palvella Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Palvella Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Palvella Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 57% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Palvella Therapeutics acquired XXX companies to date.
Last acquisition by Palvella Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Palvella Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Palvella Therapeutics founded? | Palvella Therapeutics was founded in 2015. |
| Where is Palvella Therapeutics headquartered? | Palvella Therapeutics is headquartered in United States of America. |
| How many employees does Palvella Therapeutics have? | As of today, Palvella Therapeutics has 14 employees. |
| Who is the CEO of Palvella Therapeutics? | Palvella Therapeutics's CEO is Mr. Wesley H. Kaupinen. |
| Is Palvella Therapeutics publicy listed? | Yes, Palvella Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Palvella Therapeutics? | Palvella Therapeutics trades under PVLA ticker. |
| When did Palvella Therapeutics go public? | Palvella Therapeutics went public in 2024. |
| Who are competitors of Palvella Therapeutics? | Similar companies to Palvella Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Palvella Therapeutics? | Palvella Therapeutics's current market cap is $404M |
| Is Palvella Therapeutics profitable? | Yes, Palvella Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Palvella Therapeutics? | Palvella Therapeutics's last 12 months EBITDA is -$25.3M. |
| What is the current EV/EBITDA multiple of Palvella Therapeutics? | Current EBITDA multiple of Palvella Therapeutics is -13.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
